Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Relay Therapeutics, Inc. (RLAY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/02/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/29/2023 |
4
| Patel Sanjiv (President and CEO) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 1,662 shares
@ $10.68, valued at
$17.8k
|
|
| 09/29/2023 |
4
| Rahmer Peter (See remarks) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 1,662 shares
@ $10.68, valued at
$17.8k
Sold 244 shares
@ $8.38, valued at
$2k
|
|
| 09/29/2023 |
4
| Catinazzo Thomas (CFO) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 294 shares
@ $8.38, valued at
$2.5k
|
|
| 09/29/2023 |
4
| Adams Brian (Chief Legal Officer) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 294 shares
@ $8.38, valued at
$2.5k
|
|
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue: License and other revenue $ 119 $ 365 $ 345 $ 784 Total revenue 119 365 345 784 Operating expenses: Research and development expenses $ 88,201 $ 60,511 $ 171,028 $ 112,178 Change in fair value of contingent consideration liability 200 General and administrative expenses 20,120 17,465 39,699 33,533 Total operating expenses 106,169 78,176 207,572 141,316 Loss from operations Other income: Interest income 7,559 1,005 14,500 1,701 Other income 18 Total other income, net 7,545 1,023 14,483 1,698 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average shares of common stock, basic and diluted 121,680,844 108,644,329 121,501,849 108,469,760 Other comprehensive loss: Unrealized holding ga...",
"X FGFR1 FGFR2 FGFR3 FGFR4" |
|
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/10/2023 |
SC 13G/A
| FMR LLC reports a 2.4% stake in RELAY THERAPEUTICS INC |
| 06/28/2023 |
4
| Rahmer Peter (See remarks) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 244 shares
@ $12.12, valued at
$3k
|
|
| 06/28/2023 |
4
| Catinazzo Thomas (CFO) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 294 shares
@ $12.12, valued at
$3.6k
|
|
| 06/28/2023 |
4
| Bergstrom Donald A (President, R&D) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 647 shares
@ $12.12, valued at
$7.8k
|
|
| 06/28/2023 |
4
| Adams Brian (Chief Legal Officer) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 294 shares
@ $12.12, valued at
$3.6k
|
|
| 06/01/2023 |
4
| HILL LINDA A (Director) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 66,055 options to buy
@ $11.14, valued at
$735.9k
|
|
| 06/01/2023 |
4
| INGRAM DOUGLAS S (Director) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 66,055 options to buy
@ $11.14, valued at
$735.9k
|
|
| 06/01/2023 |
4
| Kathiresan Sekar (Director) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 66,055 options to buy
@ $11.14, valued at
$735.9k
|
|
| 06/01/2023 |
4
| Murcko Mark (Director) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 66,055 options to buy
@ $11.14, valued at
$735.9k
|
|
| 06/01/2023 |
4
| Rubin Jami (Director) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 66,055 options to buy
@ $11.14, valued at
$735.9k
|
|
| 06/01/2023 |
4
| Shawver Laura (Director) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 66,055 options to buy
@ $11.14, valued at
$735.9k
|
|
| 06/01/2023 |
4
| Borisy Alexis (Director) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 66,055 options to buy
@ $11.14, valued at
$735.9k
|
|
| 06/01/2023 |
4
| Rahmer Peter (See remarks) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Granted 161,818 shares
@ $0 |
|
| 06/01/2023 |
4/A
| Rahmer Peter (See remarks) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 1,657 shares
@ $11.16, valued at
$18.5k
|
|
| 06/01/2023 |
4/A
| Catinazzo Thomas (CFO) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 2,012 shares
@ $11.16, valued at
$22.5k
|
|
| 06/01/2023 |
4/A
| Bergstrom Donald A (President, R&D) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 2,850 shares
@ $11.16, valued at
$31.8k
|
|
| 06/01/2023 |
4/A
| Adams Brian (Chief Legal Officer) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Sold 1,936 shares
@ $11.16, valued at
$21.6k
|
|
| 05/31/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/26/2023 |
4
| Shawver Laura (Director) has filed a Form 4 on Relay Therapeutics, Inc.|
Txns:
| Gifted 12,099 shares
@ $0 |
|
| 05/25/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
|
|
|